Brief: Relmada Therapeutics Announces Top-Line Results From Phase 3 Reliance I Trial For REL-1017 As Adjunctive Treatment For Major Depressive Disorder

Relmada Therapeutics

07/12/2022 21:11

Dec 7 (Reuters) - Relmada Therapeutics Inc  RLMD.O :
    * RELMADA THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PHASE
3
RELIANCE I TRIAL FOR REL-1017 AS AN ADJUNCTIVE TREATMENT FOR
MAJOR DEPRESSIVE DISORDER
    * RELMADA THERAPEUTICS INC- STUDY DID NOT ACHIEVE ITS
PRIMARY
ENDPOINT
    * RELMADA THERAPEUTICS - CONTINUES TO ENROLL PATIENTS IN
RELIANCE
II, SECOND ONGOING PHASE 3, TWO-ARM, PLACEBO-CONTROLLED, PIVOTAL
STUDY

Source text for Eikon:  ID:nPn4nGwc6a 
Further company coverage:  RLMD.O